Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 4/20 | 0.37 |
| ▸ | CASP3 | P42574 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | FABP7 | O15540 | 1/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CPA1 | P15085 | 2/20 | 0.31 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
| ▸ | CPA3 | P15088 | 1/20 | 0.31 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21979040 | 1.00 | FFAR2 (0.37) | FFAR2CASP3KMT2AMEN1TSHR | |
| SCHEMBL21978457 | 0.82 | CASP3 (0.36) | FFAR2CASP3KMT2AMEN1FABP7 | |
| SCHEMBL21978458 | 0.82 | CASP3 (0.36) | FFAR2CASP3KMT2AMEN1FABP7 | |
| SCHEMBL30065486 | 0.82 | CASP3 (0.42) | CASP3KMT2ATSHRFABP7FABP5 | |
| SCHEMBL21994849 | 0.82 | CASP3 (0.42) | CASP3KMT2ATSHRFABP7FABP5 | |
| SCHEMBL21994848 | 0.82 | CASP3 (0.42) | CASP3KMT2ATSHRFABP7FABP5 | |
| SCHEMBL21978221 | 0.81 | MEN1 (0.41) | CASP3KMT2AMEN1L3MBTL1 | |
| SCHEMBL26754271 | 0.81 | MEN1 (0.41) | CASP3KMT2AMEN1L3MBTL1 | |
| SCHEMBL21978223 | 0.81 | MEN1 (0.41) | CASP3KMT2AMEN1L3MBTL1 | |
| SCHEMBL21978041 | 0.80 | CASP3 (0.36) | FFAR2CASP3KMT2AFABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS AG (CH) | 2021-08-19 | — | — | US | disclosed |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | NOVARTIS AG (CH) | 2021-06-08 | — | — | US | disclosed |
| US-20200164024-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252103-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | FFAR2 1103/4885CASP3 397/4885KMT2A 2933/4885 |
| US-11026993-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | FFAR2 1103/4885CASP3 397/4885KMT2A 2933/4885 |
| US-11813306-B2 | Cyclic tetramer compounds as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the treatment of metabolic disorders | PCSK9, PCSK7, PCSK6 | FFAR2 1103/4885CASP3 397/4885KMT2A 2933/4885 |
| US-20200164024-A1 | CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | PCSK9, PCSK7, PCSK6 | FFAR2 1103/4885CASP3 397/4885KMT2A 2933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.